Orient EuroPharma Co., Ltd. (4120.TWO)
TWD 47.2
(-0.21%)
TWD 47.2
(-0.21%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | 120.98 Million | -218.75 Million | 77.64 Million | 608.54 Million | 227.36 Million |
| Net Income | 256.25 Million | -328.13 Million | 84.76 Million | 249.88 Million | 247.66 Million |
| Depreciation & Amortization | 216.26 Million | 194.31 Million | 191.09 Million | 196.81 Million | 182.3 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | 4.64 Million |
| Change in working capital | -157.83 Million | -205.28 Million | -55.28 Million | 212.75 Million | -293.18 Million |
| Other non-cash items | 117.95 Million | 161.21 Million | 81.75 Million | 39.71 Million | 85.94 Million |
| Investing Cash Flow | 62.1 Million | -611.56 Million | -1.49 Billion | -367.58 Million | -199.94 Million |
| Investments in PPE | -100.69 Million | -641.09 Million | -1.56 Billion | -235.11 Million | -124.97 Million |
| Acquisitions | 424.44 Million | - | -98.64 Million | - | -201.88 Million |
| Investment purchases | -258.8 Million | -84.86 Million | -86.05 Million | -217.89 Million | -257.94 Million |
| Sales/Maturities of investments | 7.67 Million | - | 48.12 Million | 95.32 Million | 263.6 Million |
| Other Investing Activities | 413.55 Million | 112.86 Million | -6.95 Million | -11.02 Million | -74.97 Million |
| Financing Cash Flow | -209.7 Million | 428.31 Million | 1.35 Billion | 222.51 Million | 63.2 Million |
| Debt repayment | -146.1 Million | -555.42 Million | -1.83 Billion | -237.38 Million | -109.41 Million |
| Dividends payments | -15.57 Million | -87.16 Million | -141.21 Million | -161.65 Million | -156.14 Million |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - |
| Other Financing Activities | 135 Thousand | -4.34 Million | -300.03 Million | 184.09 Million | 328.77 Million |
| Accounts receivables | -50.36 Million | - | - | - | 34.95 Million |
| Accounts payables | -202.1 Million | - | - | - | 34.85 Million |
| Inventory | 128.63 Million | -391.29 Million | 210.37 Million | 48.57 Million | -404.77 Million |
| Other working capital | -236.1 Million | - | - | - | 76.63 Million |
| Cash at beginning of period | 1.8 Billion | 1.95 Billion | 2.12 Billion | 1.75 Billion | 1.75 Billion |
| Cash at end of period | 1.73 Billion | 1.8 Billion | 1.95 Billion | 2.12 Billion | 1.75 Billion |
| Capital Expenditure | -100.69 Million | -641.09 Million | -1.56 Billion | -235.11 Million | -124.97 Million |
| Effect of forex changes on cash | -38.28 Million | 243.72 Million | -104.13 Million | -94.25 Million | -89.33 Million |
| Net cash flow / Change in cash | -64.9 Million | -158.28 Million | -162.09 Million | 369.22 Million | 1.28 Million |
| Free Cash Flow | 20.28 Million | -859.84 Million | -1.49 Billion | 373.43 Million | 102.39 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -18.28 Million | -55.02 Million | 256.25 Million | 443.15 Million | -28.79 Million | -214.98 Million |
| Depreciation & Amortization | 52.47 Million | 52.83 Million | 216.26 Million | 54.23 Million | 55.13 Million | 54.23 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -97.25 Million | -208.05 Million | -157.83 Million | 16.5 Million | -159.18 Million | 33.06 Million |
| Other non-cash items | 30.45 Million | 13.42 Million | 117.95 Million | 37.52 Million | 45.64 Million | 16.7 Million |
| Investing Cash Flow | -81.45 Million | -155.95 Million | 62.1 Million | 213.79 Million | 42.4 Million | -101.29 Million |
| Investments in PPE | -23.82 Million | -17.4 Million | -100.69 Million | -4.68 Million | -22.75 Million | -60.54 Million |
| Acquisitions | -3.85 Million | -107.19 Million | - | - | - | - |
| Investment purchases | -64.72 Million | -31.37 Million | -258.8 Million | -208.6 Million | 71.32 Million | -42.55 Million |
| Sales/Maturities of investments | 63.1 Million | - | 7.67 Million | - | - | - |
| Other Investing Activities | 10.61 Million | -631 Thousand | 413.55 Million | 419.71 Million | -6.37 Million | 1.5 Million |
| Financing Cash Flow | 87.27 Million | 28.99 Million | -209.7 Million | -446.48 Million | 90.23 Million | 55.99 Million |
| Debt repayment | -107.49 Million | -70.53 Million | -146.1 Million | -427.59 Million | -102.68 Million | -76.36 Million |
| Dividends payments | - | - | -15.57 Million | -6.82 Million | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -374 Thousand | -29.92 Million | 135 Thousand | -274 Thousand | -359 Thousand | 672 Thousand |
| Accounts receivables | 32.25 Million | - | - | - | - | - |
| Accounts payables | -16.35 Million | - | - | - | - | - |
| Inventory | -85.83 Million | 32.82 Million | 128.63 Million | 103.85 Million | -12.71 Million | 14.35 Million |
| Other working capital | -27.31 Million | - | - | - | - | - |
| Cash at beginning of period | 1.55 Billion | 1.73 Billion | 1.8 Billion | 1.85 Billion | 1.74 Billion | 1.84 Billion |
| Cash at end of period | 1.39 Billion | 1.55 Billion | 1.73 Billion | 1.73 Billion | 1.85 Billion | 1.74 Billion |
| Capital Expenditure | -23.82 Million | -17.4 Million | -100.69 Million | -4.68 Million | -22.75 Million | -60.54 Million |
| Effect of forex changes on cash | 10.86 Million | 59.64 Million | -38.28 Million | -178.36 Million | 95.08 Million | 70.01 Million |
| Net cash flow / Change in cash | -161.71 Million | -177.28 Million | -64.9 Million | -119.72 Million | 111.17 Million | -103.05 Million |
| Free Cash Flow | -202.22 Million | -127.38 Million | 20.28 Million | 286.65 Million | -139.3 Million | -188.3 Million |
CRRVF
6916
CASI
300166
LBTL
BRN